Novel Delivery of Controlled-Release Nanoparticles Shows Promise for Treating High Grade Glioma Brain Tumors
American Association of Neurological Surgeons (AANS)In 2007, an estimated 20,500 new cases of primary malignant brain and central nervous system tumors were diagnosed and approximately 12,740 deaths were attributed to these tumors. High grade glioma is the most common malignancy, as well as the most devastating. Research investigates potential of targeted delivery of controlled-release nanoparticles.